Van Cleef Asset Management Inc Purchases Shares of 5,155 Eli Lilly and Co (LLY)

Van Cleef Asset Management Inc acquired a new stake in Eli Lilly and Co (NYSE:LLY) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 5,155 shares of the company’s stock, valued at approximately $435,000.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and by 2.3% in the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after purchasing an additional 1,610,885 shares during the last quarter. BlackRock Inc. grew its position in Eli Lilly and by 2.1% during the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after buying an additional 1,323,259 shares during the period. Janus Henderson Group PLC grew its position in Eli Lilly and by 16.1% during the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after buying an additional 1,503,918 shares during the period. Dodge & Cox grew its position in Eli Lilly and by 22,094.9% during the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after buying an additional 5,964,955 shares during the period. Finally, Renaissance Technologies LLC grew its position in Eli Lilly and by 91.1% during the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after buying an additional 2,714,505 shares during the period. 76.45% of the stock is currently owned by institutional investors.

In other news, insider Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the sale, the insider now owns 4,130 shares in the company, valued at approximately $334,901.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now owns 54,885 shares in the company, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 259,610 shares of company stock worth $22,727,406. 0.20% of the stock is currently owned by company insiders.

LLY has been the subject of several research reports. Jefferies Group set a $100.00 price target on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Tuesday, January 16th. Goldman Sachs Group lowered shares of Eli Lilly and from a “buy” rating to a “neutral” rating and raised their price objective for the company from $86.98 to $95.00 in a research report on Tuesday, January 16th. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and raised their price objective for the company from $85.52 to $115.00 in a research report on Friday, January 5th. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 5th. Finally, Bank of America lowered their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research note on Thursday, February 1st. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $92.02.

Shares of Eli Lilly and Co (LLY) traded up $2.02 during trading on Friday, hitting $76.23. 8,923,892 shares of the stock traded hands, compared to its average volume of 6,073,832. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Co has a 1 year low of $73.69 and a 1 year high of $89.09. The company has a market capitalization of $83,936.48, a PE ratio of -381.13, a price-to-earnings-growth ratio of 1.40 and a beta of 0.23.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The business’s revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the business earned $0.95 earnings per share. analysts forecast that Eli Lilly and Co will post 4.88 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a yield of 2.95%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is -1,039.95%.

ILLEGAL ACTIVITY WARNING: “Van Cleef Asset Management Inc Purchases Shares of 5,155 Eli Lilly and Co (LLY)” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2018/02/11/van-cleef-asset-management-inc-acquires-new-holdings-in-eli-lilly-and-co-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply